A report in Bloomberg cites a registration in the Chinese Clinical Trial Registry confirming that the nasal spray vaccine candidate developed by Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise is undergoing Phase I human testing.
IN CASE YOU MISSED IT
- Dexcom, RxFood partner on AI-based nutrition, glucose monitoring for diabetes management
- Abbott completes Bigfoot Biomedical acquisition
- Medtronic wins CE mark for next-gen Simplera CGM with InPen integration
- FDA requests more info on neffy needle-free epinephrine
- Ypsomed concludes autoinjector supply deal with Novo Nordisk
About Sean Whooley
Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.